Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,283 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Treatment outcome of myelodysplastic syndrome patients younger than 60 years old].
Matsushima T, Handa H, Yokohama A, Sakura T, Okamoto K, Kawamura T, Tsumita Y, Murayama K, Isoda A, Jinbo T, Hirabyashi H, Sawamura M, Karasawa M, Shimano S, Tsukamoto N, Miyawaki S, Nojima Y, Murakami H. Matsushima T, et al. Among authors: murakami h. Rinsho Ketsueki. 2003 Oct;44(10):1004-9. Rinsho Ketsueki. 2003. PMID: 14639946 Japanese.
Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.
Murakami H, Handa H, Abe M, Iida S, Ishii A, Ishikawa T, Ishida T, Oota M, Ozaki S, Kosaka M, Sakai A, Sawamura M, Shimazaki C, Shimizu K, Takagi T, Hata H, Fukuhara T, Fujii H, Miyata A, Wakayama T, Takatsuki K. Murakami H, et al. Eur J Haematol. 2007 Sep;79(3):234-9. doi: 10.1111/j.1600-0609.2007.00908.x. Epub 2007 Jul 26. Eur J Haematol. 2007. PMID: 17655699 Clinical Trial.
A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma.
Kodama T, Abe M, Iida S, Ozaki S, Sakai A, Sawamura M, Shimazaki C, Miyata A, Wakayama T, Murakami H. Kodama T, et al. Among authors: murakami h. Clin Lymphoma Myeloma. 2009 Apr;9(2):154-9. doi: 10.3816/CLM.2009.n.037. Clin Lymphoma Myeloma. 2009. PMID: 19406727
[Retrospective survey on the clinical features of non-Hodgkin lymphomas in Gunma Prefecture, Japan].
Hashimoto Y, Yokohama A, Saitoh A, Nakahashi H, Toyama K, Mitsui T, Koiso H, Saitoh T, Handa H, Uchiumi H, Jinbo T, Murayama K, Tamaki Y, Matsumoto M, Sawamura M, Karasawa M, Murakami H, Hirato J, Nojima Y, Kojima M, Tsukamoto N. Hashimoto Y, et al. Among authors: murakami h. Rinsho Ketsueki. 2012 Mar;53(3):329-36. Rinsho Ketsueki. 2012. PMID: 22499050 Japanese.
SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients.
Mitsui T, Koiso H, Nakahashi H, Saitoh A, Shimizu H, Ishizaki T, Ogawa Y, Takizawa M, Yokohama A, Saitoh T, Jinbo T, Ogura H, Handa H, Sawamura M, Sakura T, Karasawa M, Murakami H, Nojima Y, Tsukamoto N. Mitsui T, et al. Among authors: murakami h. Int J Hematol. 2016 Feb;103(2):219-26. doi: 10.1007/s12185-015-1912-z. Epub 2015 Nov 20. Int J Hematol. 2016. PMID: 26588928
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ozaki S, Hata H, Abe M, Saitoh T, Hanamura I, Yano H, Sunami K, Kosugi H, Sawamura M, Nakazato T, Masunari T, Mori M, Takagi T, Murakami H, Shimizu K. Ozaki S, et al. Among authors: murakami h. Ann Hematol. 2016 May;95(6):921-9. doi: 10.1007/s00277-016-2661-7. Epub 2016 Apr 5. Ann Hematol. 2016. PMID: 27044390 Clinical Trial.
3,283 results